Cargando…
Targeted Extracellular Vesicle Gene Therapy for Modulating Alpha-Synuclein Expression in Gut and Spinal Cord
The development of effective disease-modifying therapies to halt Parkinson’s disease (PD) progression is required. In a subtype of PD patients, alpha-synuclein pathology may start in the enteric nervous system (ENS) or autonomic peripheral nervous system. Consequently, strategies to decrease the exp...
Autores principales: | Izco, Maria, Schleef, Martin, Schmeer, Marco, Carlos, Estefania, Verona, Guglielmo, Alvarez-Erviti, Lydia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145068/ https://www.ncbi.nlm.nih.gov/pubmed/37111717 http://dx.doi.org/10.3390/pharmaceutics15041230 |
Ejemplares similares
-
Oral Sub-Chronic Ochratoxin a Exposure Induces Gut Microbiota Alterations in Mice
por: Izco, María, et al.
Publicado: (2021) -
Spinal Cord Pathology in Alpha-Synuclein Transgenic Mice
por: Mendritzki, Sonja, et al.
Publicado: (2010) -
Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission
por: Alvarez-Erviti, Lydia, et al.
Publicado: (2011) -
Toxicity of extracellular alpha-synuclein is independent of intracellular alpha-synuclein
por: Dening, Yanina, et al.
Publicado: (2022) -
Comparison of alpha-synuclein immunoreactivity in the spinal cord between the adult and aged beagle dog
por: Ahn, Ji-Hyeon, et al.
Publicado: (2012)